Table 1.

Characteristics of patients with ANCA-associated GN at the time of trial enrollment stratified by presence of persistent hematuria

CharacteristicAll, n=149Persistent Hematuria beyond 6 mo
Yes, n=63No, n=86
Age, yr55 (44–66)54 (43–68)55 (44–63)
Women, %415630
Achieved menopause (if a woman), %625177
Race, %
ANCA-associated vasculitis type, %
 Granulomatosis with polyangiitis817187
 Microscopic polyangiitis192913
ANCA type by ELISA, %
Duration of trial enrollment, mo36 (24–43)36 (25–46)36 (24–42)
Newly diagnosed, %595760
BVAS/GPA7 (5–10)8 (6–10)7 (4–9)
Vasculitis damage index0 (0–1)0 (0–1)0 (0–1)
Pulmonary involvement, %605465
 Alveolar hemorrhage, %263023
Induction therapy, %
Cumulative dose of cyclophosphamide before enrollment, g0.8 (0–24.0)0 (0–26)1.2 (0–17.6)
Characteristics of kidney disease
 Prior kidney involvement, %9810094
 Ever required dialysis, %332
 Serum creatinine at enrollment, mg/dl1.4 (1.1–2.3)1.8 (1.1–2.6)1.3 (1–2.2)
Manifestations at enrollment, %
  Red blood cell castsa566252
  Rise in serum creatininea506341
 Duration of persistent hematuria, mo6 (3–12)17 (11–26)3 (2–4)
 Persistent proteinuria ≥6 mo, %436031
  • Values are expressed as medians (interquartile ranges) or percentages. he conversion factor for serum creatinine in milligrams per deciliter to micromoles per liter is ×88.4. PR3, proteinase 3; MPO, myeloperoxidase; BVAS/GPA, Birmingham Vasculitis Activity Score for Granulomatosis with Polyangiitis.

  • a On the basis of Birmingham Vasculitis Activity Score for Wegener Granulomatosis items.